Black Diamond Therapeutics Presented Novel Real-World Evidence Of The Evolving EGFR Mutation Landscape In NSCLC And The Opportunity For BDTX-1535 In An Oral Presentation At The 2024 AACR Annual Meeting
$BDTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC
- Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib
- BDTX-1535 profile differentiated as the most advanced fourth-generation oral TKI in clinical development addressing the full spectrum of classical, non-classical, and C797S resistance EGFR mutations